Free Trial

Amicus Therapeutics (FOLD) News Today

→ Was the Great Financial Crisis fun? (From Brooks Enterprises) (Ad)
Free FOLD Stock Alerts
$10.05
-0.22 (-2.14%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 8 at 7:16 PM | marketbeat.com
Seven Eight Capital LP Has $2 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Seven Eight Capital LP grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 313.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 140,581 shares of the
June 7 at 1:26 AM | americanbankingnews.com
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.57
June 6 at 4:44 AM | marketbeat.com
Wells Fargo & Company MN Trims Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Wells Fargo & Company MN lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 570,956 shares of the biopharmaceuti
June 5 at 1:06 PM | globenewswire.com
In NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private Funds
June 5 at 8:32 AM | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Rafferty Asset Management LLC
Rafferty Asset Management LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 795,351 shares of the biop
June 5 at 7:00 AM | globenewswire.com
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024 | marketbeat.com
Campbell & CO Investment Adviser LLC Has $2.42 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Campbell & CO Investment Adviser LLC grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1,447.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 170,431 shares of the biopharmaceutical company's stock after purch
June 4, 2024 | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy
June 4, 2024 | americanbankingnews.com
Amicus Therapeutics, Inc. Expected to Post Q3 2025 Earnings of $0.05 Per Share (NASDAQ:FOLD)
June 3, 2024 | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Forecasted to Earn Q3 2025 Earnings of $0.05 Per Share
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities researchers at Zacks Research cut their Q3 2025 EPS estimates for Amicus Therapeutics in a research note issued to investors on Thursday, May 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical comp
June 2, 2024 | marketbeat.com
UBS Group AG Acquires 303,038 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
UBS Group AG boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 58.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 824,708 shares of the biopharmaceutical company's stock after purcha
June 1, 2024 | americanbankingnews.com
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.36
May 31, 2024 | marketbeat.com
Norges Bank Acquires New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Norges Bank acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 2,531,000 shares of the biopharmaceutical company's stock, valued at approximately
May 30, 2024 | americanbankingnews.com
Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Analysts at Wells Fargo & Company
May 24, 2024 | msn.com
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
May 22, 2024 | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,268,886 shares of the biopharmaceutical company's stoc
May 20, 2024 | seekingalpha.com
Amicus Therapeutics: Too Cheap At Under $10 A Share
May 18, 2024 | marketbeat.com
Massachusetts Financial Services Co. MA Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Massachusetts Financial Services Co. MA increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 32.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,415,090
May 16, 2024 | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by BNP Paribas Financial Markets
BNP Paribas Financial Markets boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 138.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 923,045 shares of the biopharmaceutical company's stock after purchasing an addition
May 15, 2024 | marketbeat.com
M&G Investment Management Ltd. Takes $9.95 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
M&G Investment Management Ltd. acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 710,557 shares of the biopharm
May 14, 2024 | msn.com
Guggenheim Upgrades Amicus Therapeutics (FOLD)
May 14, 2024 | markets.businessinsider.com
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
May 14, 2024 | marketbeat.com
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04
May 14, 2024 | marketbeat.com
Amicus Therapeutics (NASDAQ:FOLD) Upgraded by Guggenheim to "Buy"
Guggenheim upgraded Amicus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a report on Tuesday.
May 10, 2024 | marketbeat.com
Amicus Therapeutics (NASDAQ:FOLD) Issues Earnings Results
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. The business had revenue of $110.40 million during the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. Amicus Therapeutics's quarterly revenue was up 27.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.18) earnings per share.
May 10, 2024 | marketbeat.com
Amicus Therapeutics (NASDAQ:FOLD) PT Lowered to $19.00 at UBS Group
UBS Group cut their target price on Amicus Therapeutics from $20.00 to $19.00 and set a "buy" rating for the company in a research report on Friday.
May 10, 2024 | finance.yahoo.com
Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...
May 10, 2024 | finance.yahoo.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript
May 10, 2024 | marketbeat.com
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Friday.
May 10, 2024 | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Buy" from Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average recommendation of "Buy" from the three research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a buy rating. The average twelve-month
May 9, 2024 | investorplace.com
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 9, 2024 | marketbeat.com
Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week Low at $9.30
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year Low at $9.30
May 9, 2024 | washingtonpost.com
Amicus Therapeutics: Q1 Earnings Snapshot
May 9, 2024 | globenewswire.com
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
May 9, 2024 | marketbeat.com
Victory Capital Management Inc. Cuts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Victory Capital Management Inc. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 40.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,687 sh
May 8, 2024 | globenewswire.com
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
May 8, 2024 | barrons.com
Amicus Therapeutics Inc.
May 4, 2024 | insidertrades.com
Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 7,500 Shares of Stock
May 2, 2024 | marketbeat.com
Amicus Therapeutics (FOLD) to Release Quarterly Earnings on Thursday
Amicus Therapeutics (NASDAQ:FOLD) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.
May 1, 2024 | globenewswire.com
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
April 21, 2024 | marketbeat.com
Vontobel Holding Ltd. Purchases New Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Vontobel Holding Ltd. purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 82,672 shares of the biopharmaceutical company's stock, valued at approximately $1,173,000.
April 14, 2024 | nasdaq.com
Amicus Therapeutics Becomes Oversold (FOLD)
April 10, 2024 | marketbeat.com
Peregrine Capital Management LLC Reduces Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Peregrine Capital Management LLC reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 16.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 605,348 shares of the biopharmaceutical company's
March 30, 2024 | msn.com
Nevada’s Lee joins on to Amicus Brief in SCOTUS abortion case
March 29, 2024 | msn.com
Nevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion case
March 28, 2024 | marketbeat.com
Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5%
Amicus Therapeutics (NASDAQ:FOLD) Trading Down 2.5%
March 27, 2024 | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Vanguard Group Inc.
Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,131,873 shares of the biopharmaceutical
March 22, 2024 | marketbeat.com
Zacks Research Comments on Amicus Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Zacks Research boosted their Q1 2024 earnings per share estimates for Amicus Therapeutics in a report released on Wednesday, March 20th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings
March 21, 2024 | marketbeat.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q3 2024 Earnings of $0.01 Per Share, Zacks Research Forecasts
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Stock analysts at Zacks Research issued their Q3 2024 EPS estimates for shares of Amicus Therapeutics in a research report issued on Wednesday, March 20th. Zacks Research analyst R. Department expects that the biopharmaceutical company will
March 20, 2024 | marketbeat.com
Amicus Therapeutics Target of Unusually High Options Trading (NASDAQ:FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) saw some unusual options trading on Wednesday. Stock traders acquired 10,103 call options on the company. This is an increase of approximately 1,275% compared to the typical volume of 735 call options.
Get Amicus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Was the Great Financial Crisis fun? (Ad)

The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red.

Get those kind of results during the Great Financial Crisis, without having to study more

FOLD Media Mentions By Week

FOLD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FOLD
News Sentiment
▼
0.61

0.73
▲
Average
Medical
News Sentiment

FOLD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FOLD Articles
This Week
▼
14

4
▲
FOLD Articles
Average Week

Get Amicus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:FOLD) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Gold Set to EXPLODE!
The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...
Gold Safe Exchange | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Was the Great Financial Crisis fun?
The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...
Brooks Enterprises | Sponsored
Biden Nomination CANCELED?
And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...
The Freeport Society | Sponsored